Cochrane Summary: Human recombinant activated protein C for severe sepsis and septic shock in adult and paediatric patients (2012)

Cochrane Summary: Human recombinant activated protein C for severe sepsis and septic shock in adult and paediatric patients (2012)

Visit Visit

Objective: In this updated Cochrane review we searched the databases until June 2012. We included six randomized clinical trials which involved 6781 people (6307 adult and 474 paediatric participants) with either a high or low risk of death. All trials had high risk of bias and were sponsored by the pharmaceutical industry (Eli Lilly). moreover, there is an increased risk of bleeding associated with its use. Published: 2012.